J Clin Oncol 24 (31): 4956-62, 2006.[PUBMED Abstract] Wolff AC, Davidson NE: Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer.
J Clin Oncol 24 (31): 4949-51, 2006.[PUBMED Abstract] Boccardo F, Rubagotti A, Amoroso D, et al.: Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial.
boccardo@hp380.ist.unige.it.
J Clin Oncol 18 (14): 2718-27, 2000.[PUBMED Abstract] Winer EP, Hudis C, Burstein HJ, et al.: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.